<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012411</url>
  </required_header>
  <id_info>
    <org_study_id>19_0081</org_study_id>
    <nct_id>NCT04012411</nct_id>
  </id_info>
  <brief_title>Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease</brief_title>
  <acronym>LCR-MH</acronym>
  <official_title>Study of Brain Derived Neurotrophic Factor (BDNF) Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Huntington disease (HD, 1.3/10 000) is an autosomal dominant disease due to an abnormal&#xD;
      expansion of CAG triplets in HTT gene.&#xD;
&#xD;
      Several pathophysiological mechanisms have been evoked, including an alteration of the&#xD;
      signaling pathway of the Brain Derived Neurotrophic Factor (BDNF), a neurotrophic factor&#xD;
      involved in the survival of neurons (striatal and hippocampal) and synaptic plasticity. BDNF&#xD;
      is synthesized at the level of cortical neurons and transported, through the axonal transport&#xD;
      in which the Htt is involved, to the nerve endings; it's then secreted in response to&#xD;
      excitatory synaptic activity, especially at the level of glutamatergic synapses. Besides, at&#xD;
      the postsynaptic level it binds with great specificity to TrkB receptors (tropomyosin-related&#xD;
      kinase receptors B) with a neuroprotective effect on dendritic and axonal growth and an&#xD;
      increase in synaptic plasticity, especially at the level of the striatum and the hippocampus.&#xD;
&#xD;
      BDNF is decreased in the brain of animal models, as well as in patients with HD; the&#xD;
      alteration of this pathway would occur in the early stages of the disease.&#xD;
&#xD;
      In the context of concomitant multiple treatments, the BNDF pathway may be one of the&#xD;
      therapeutic targets of HD.&#xD;
&#xD;
      Moreover, in HD it remains essential to detect biological markers representative of the&#xD;
      different pathogenic pathways that can be tested in vivo in humans to confirm the hypotheses&#xD;
      developed at the level of basic research; these biomarkers could subsequently become&#xD;
      biomarkers of disease progression and/or biomarkers of therapeutic efficacy of potential&#xD;
      targeted treatments.&#xD;
&#xD;
      Therefore, this study aims to characterize potential biomarkers of the BNDF pathway in plasma&#xD;
      and CSF in subjects with HD and to confirm the importance of this pathogenic mechanism in&#xD;
      vivo in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Design: Multicentre prospective case-control study. Centres: University Hospital of&#xD;
           Montpellier, France; University Hospital of Bordeaux, France; University Hospital of&#xD;
           Nimes, France; University Hospital of Poitiers, France.&#xD;
&#xD;
        -  Main objective: To evaluate BDNF in cerebrospinal fluid as a potential marker of the&#xD;
           BDNF-TrkB signaling pathway in vivo in HD patients at a symptomatic stage.&#xD;
&#xD;
        -  Secondary objectives: i) Evaluate plasma BDNF in subjects with HD; ii) Study the&#xD;
           correlation between BDNF in CSF and BDNF in plasma; iii) Study the correlation between&#xD;
           markers of the BDNF pathway and clinical severity, multimodal brain MRI parameters, and&#xD;
           relevant markers of evolution of HD; iv) Confirm the increase of Tau and NFL&#xD;
           (Neurofilament Light Chain) markers in plasma and in CSF, as markers of neuronal&#xD;
           degeneration, in subjects with HD ; v) Test the TrkB assay in the CSF of patients with&#xD;
           HD&#xD;
&#xD;
        -  Inclusion Criteria. General inclusion criteria: age ≥ 18 years old; national health&#xD;
           insurance cover. Patient inclusion criteria: genetically confirmed Huntington's disease&#xD;
           diagnosis (≥ 35 CAG repeat in HTT gene exon 1); written informed consent; patient&#xD;
           agreement for LP, if requested. Control inclusion criteria: previous LP for medical&#xD;
           reason; agreement for inclusion in a biobank for research purposes.&#xD;
&#xD;
        -  Exclusion Criteria. General exclusion criteria: subject protected by law, under&#xD;
           curatorship or guardianship. Patients exclusion criteria: too severe HD, according to&#xD;
           the clinician's judgment, possibly making difficult to perform cognitive evaluation or&#xD;
           MRI; contraindications to brain MRI; contraindications to LP; inability to give informed&#xD;
           consent. Control exclusion criteria: presence of a neurodegenerative of inflammatory&#xD;
           central nervous system disease.&#xD;
&#xD;
        -  Inclusion period: 23 months&#xD;
&#xD;
        -  Duration of participation for each patient: 123 days maximum&#xD;
&#xD;
        -  Total research duration: 24 months&#xD;
&#xD;
        -  Plan of the study. Patients group: in 90 patients with HD, the investigators will&#xD;
           perform: a collection of the main anamnestic and clinical data; a blood test for the&#xD;
           determination of plasmatic BDNF, Tau and NFL and the genotyping of the Val66Met&#xD;
           polymorphism of the BDNF gene; multimodal brain MRI with volumetry, diffusion tensor,&#xD;
           functional MRI of rest; a measurement of the severity of Huntington's disease and Total&#xD;
           Functional Capacity scales; neuropsychological tests (SDMT, STROOP test, Trail Making&#xD;
           Test (TMT) A and B, digit span). In a subgroup of 45 patients, the investigators will&#xD;
           also perform a lumbar puncture for the determination of BDNF, Tau, NFL and TrkB in CSF.&#xD;
           Control Group: 45 controls will be selected from the samples present in the existing&#xD;
           Biobank with CSF and plasma samples available in Montpellier, France. MRI data will be&#xD;
           centralized and processed by the Imaging Institute I2FH Montpellier University Hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BDNF(csf) in HD subjects compared to age-matched control subjects (+/- 5 years)</measure>
    <time_frame>Inclusion</time_frame>
    <description>centralized ELISA assay with Simoa - Quanterix kit technology at the Laboratory of Clinical Proteomic Biochemistry of Montpellier, France.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasmatic BDNF in HD subjects vs controls</measure>
    <time_frame>Inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between BDNF in CSF and BDNF in plasma</measure>
    <time_frame>Inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between BDNF and disease parameters</measure>
    <time_frame>Inclusion</time_frame>
    <description>Correlation between BDNF in CSF or plasma and: disease severity, assessed through a Scale that quantifies the severity of the disease, the disease burden formula [(n.CAG-35.5) x age], the Total Functional Capacity functional scale (TFC), and cognitive scales (Symbol Digit Modalities Test, STROOP test, Trail Making test A and B, direct and indirect digit span); - MRI brain imaging: cerebral and striatal atrophy by morphological imaging, functional resting state MRI, and anatomical connectivity by diffusion tensor imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Tau and NFL levels in plasma and CSF in HD subjects vs control subjects</measure>
    <time_frame>Inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TrkBcsf level in subjects with HD vs control subjects</measure>
    <time_frame>Inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Patient with LP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Huntington's disease patients who agreed to have LP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient without LP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Huntington's disease patient with contraindication to LP or refusal to have LP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Retrospective study with biologic samples of patients without Huntington's disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brain MRI</intervention_name>
    <description>Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI</description>
    <arm_group_label>Patient with LP</arm_group_label>
    <arm_group_label>Patient without LP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar Punction</intervention_name>
    <description>Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid</description>
    <arm_group_label>Patient with LP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Analysis of BDNF, Tau, NFL, and Val66Met polymorphism</description>
    <arm_group_label>Patient with LP</arm_group_label>
    <arm_group_label>Patient without LP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive evaluation</intervention_name>
    <description>Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan</description>
    <arm_group_label>Patient with LP</arm_group_label>
    <arm_group_label>Patient without LP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General inclusion criteria:&#xD;
&#xD;
               -  age ≥ 18 years-old&#xD;
&#xD;
               -  national health insurance cover&#xD;
&#xD;
          -  Patients inclusion criteria:&#xD;
&#xD;
               -  genetically confirmed Huntington's disease diagnosis (≥ 35 CAG repeat in HTT gene&#xD;
                  exon 1)&#xD;
&#xD;
               -  written informed consent&#xD;
&#xD;
               -  only for patients &quot;with lumbar puncture (LP)&quot;: patient agreement for LP&#xD;
&#xD;
          -  Control inclusion criteria:&#xD;
&#xD;
               -  anterior LP for medical reason with consent for biobank &quot;Neuro&quot; with following&#xD;
                  samples present in this biobank : 2 mL blood + 0.5 mL plasma + 0.5 mL&#xD;
                  cerebrospinal fluid&#xD;
&#xD;
               -  information and non-opposition for the finality of this biobank&#xD;
&#xD;
               -  paired by age with a patient (+/- 5 years difference)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General exclusion criteria:&#xD;
&#xD;
               -  protected by law&#xD;
&#xD;
          -  Patients exclusion criteria:&#xD;
&#xD;
               -  Huntington's disease stage too Evolved that may interfere with cognitive&#xD;
                  evaluations or MRI&#xD;
&#xD;
               -  contraindications to brain MRI&#xD;
&#xD;
               -  only for patients &quot;with LP&quot;: contraindications to LP&#xD;
&#xD;
               -  incapacity to give informed consent&#xD;
&#xD;
          -  Control exclusion criteria:&#xD;
&#xD;
               -  neurodegenerative of inflammatory central nervous system pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Marelli</last_name>
      <email>c-marelli@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Diana Ban</last_name>
      <email>d-ban@chu-montpellier.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huntington Disease</keyword>
  <keyword>CSF</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>BDNF</keyword>
  <keyword>P42</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

